Bruker (BRKRP) Equity Ratio (2010 - 2026)
Bruker posted quarterly Equity Ratio of 0.4 for Q1 2026, up 30.26% year-on-year from 0.31 in Q1 2025, and up 1.54% on a QoQ basis from 0.4 in Q4 2025.
Bruker (BRKRP) has 17 years of Equity Ratio data on file, last reported at 0.4 in Q1 2026.
- For the quarter ending Q1 2026, Equity Ratio rose 30.26% year-over-year to 0.4; the trailing twelve-month figure through Mar 2026 stood at 0.4 (up 30.26% YoY), and the FY2025 full-year result was 0.4, up 28.05% from the prior year.
- Equity Ratio for Q1 2026 stood at 0.4, up from 0.4 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.4 in Q1 2026 and bottomed at 0.28 in Q3 2022.
- The 5-year median for Equity Ratio is 0.31 (2022), against an average of 0.32.
- The widest annual swing landed in 2022, when Equity Ratio fell 18.45%; it then surged 30.26% in 2026.
- A 5-year view of Equity Ratio shows it stood at 0.31 in 2022, then rose by 5.29% to 0.33 in 2023, then fell by 5.69% to 0.31 in 2024, then increased by 28.05% to 0.4 in 2025, then climbed by 1.54% to 0.4 in 2026.
- The last three Equity Ratio figures came in at 0.4 (Q1 2026), 0.4 (Q4 2025), and 0.38 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.47 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.50 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.54 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.59 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.78 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.45 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.29 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.67 |
| 10 | Bruker | - | - | 379.80 Mn | 0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.40 |
| Dec 31, 2025 | 0.40 |
| Sep 30, 2025 | 0.38 |
| Jun 30, 2025 | 0.29 |
| Mar 31, 2025 | 0.31 |
| Dec 31, 2024 | 0.31 |
| Sep 30, 2024 | 0.30 |
| Jun 30, 2024 | 0.31 |
| Mar 31, 2024 | 0.32 |
| Dec 31, 2023 | 0.33 |
| Sep 30, 2023 | 0.32 |
| Jun 30, 2023 | 0.32 |
| Mar 31, 2023 | 0.32 |
| Dec 31, 2022 | 0.31 |
| Sep 30, 2022 | 0.28 |
| Jun 30, 2022 | 0.29 |
| Mar 31, 2022 | 0.29 |
| Dec 31, 2021 | 0.30 |
| Sep 30, 2021 | 0.35 |
| Jun 30, 2021 | 0.33 |
| Mar 31, 2021 | 0.32 |
| Dec 31, 2020 | 0.32 |
| Sep 30, 2020 | 0.33 |
| Jun 30, 2020 | 0.31 |
| Mar 31, 2020 | 0.31 |
| Dec 31, 2019 | 0.33 |
| Sep 30, 2019 | 0.36 |
| Jun 30, 2019 | 0.37 |
| Mar 31, 2019 | 0.41 |
| Dec 31, 2018 | 0.43 |
| Sep 30, 2018 | 0.44 |
| Jun 30, 2018 | 0.43 |
| Mar 31, 2018 | 0.43 |
| Dec 31, 2017 | 0.38 |
| Sep 30, 2017 | 0.38 |
| Jun 30, 2017 | 0.40 |
| Mar 31, 2017 | 0.39 |
| Dec 31, 2016 | 0.38 |
| Sep 30, 2016 | 0.39 |
| Jun 30, 2016 | 0.39 |
| Mar 31, 2016 | 0.40 |
| Dec 31, 2015 | 0.42 |
| Sep 30, 2015 | 0.41 |
| Jun 30, 2015 | 0.42 |
| Mar 31, 2015 | 0.40 |
| Dec 31, 2014 | 0.41 |
| Sep 30, 2014 | 0.43 |
| Jun 30, 2014 | 0.44 |
| Mar 31, 2014 | 0.43 |
| Dec 31, 2013 | 0.43 |
| Sep 30, 2013 | 0.40 |
| Jun 30, 2013 | 0.40 |
| Mar 31, 2013 | 0.38 |
| Dec 31, 2012 | 0.38 |
| Sep 30, 2012 | 0.38 |
| Jun 30, 2012 | 0.36 |
| Mar 31, 2012 | 0.37 |
| Dec 31, 2011 | 0.37 |
| Sep 30, 2011 | 0.36 |
| Jun 30, 2011 | 0.37 |
| Mar 31, 2011 | 0.35 |
| Dec 31, 2010 | 0.34 |